Robert Galemmo

Head of Medicinal Chemistry at Verge Genomics

Dr. Galemmo has led teams responsible for multiple clinical and development candidates in the pharmaceutical and biotech industries. He initiated the research effort for the marketed oral anti-coagulant Eliquis®, led the team that identified the MET kinase inhibitor JNJ 38877605 under clinical development in the EU, and discovered the clinical leukotriene antagonist RG 12525 for asthma. He has broad therapeutic area experience in Oncology, CNS, CV, GI, and anti-inflammation drug research. Dr. Galemmo is named as an inventor on 42 US patents and the author of more than 50 scientific publications.


  • Head of Medicinal Chemistry

    Current role

  • Interim Head of Medicinal Chemistry

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.